Congratulations to Alnylam Pharmaceuticals on the FDA Approval of Amvuttra.

Written By Kimberly Hicks
Kimberly Hicks
Previous

Pathos has officially dosed the first patient in its Phase 1b/2a clinical trial evaluating Pocenbrodib.

Next

Dewpoint Therapeutics succeeds in the nomination of DPTX3496 as their second development candidate!